Agilent Technologies (NYSE:A) Upgraded at Wall Street Zen

Key Points

• Agilent Technologies has been upgraded from a "hold" rating to a "buy" rating by investment analysts at Wall Street Zen.
• Several analysts, including Wells Fargo and Barclays, have raised their price targets for the stock, with the average target now at $142.17.
• The company reported quarterly earnings of $1.37 EPS, matching analysts' expectations, and showed a 10.1% increase in revenue year-over-year.

Agilent Technologies (NYSE:A - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a research note issued to investors on Friday.

A number of other analysts also recently weighed in on A. Wells Fargo & Company increased their price target on Agilent Technologies from $140.00 to $150.00 and gave the stock an "overweight" rating in a report on Monday, September 15th. Barclays increased their price target on Agilent Technologies from $125.00 to $150.00 and gave the stock an "equal weight" rating in a report on Thursday. Evercore ISI cut their price target on Agilent Technologies from $130.00 to $128.00 and set an "in-line" rating on the stock in a report on Thursday, August 28th. Robert W. Baird increased their price target on Agilent Technologies from $141.00 to $142.00 and gave the stock an "outperform" rating in a report on Thursday, August 28th. Finally, Weiss Ratings reiterated a "hold (c)" rating on shares of Agilent Technologies in a research note on Saturday, September 27th. Six investment analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. According to data from MarketBeat, Agilent Technologies has an average rating of "Hold" and an average target price of $142.17.

Agilent Technologies Price Performance

NYSE A traded up $3.21 on Friday, hitting $141.91. 2,345,955 shares of the company's stock were exchanged, compared to its average volume of 1,813,153. The stock has a 50-day moving average of $122.80 and a 200-day moving average of $116.41. The company has a current ratio of 2.25, a quick ratio of 1.71 and a debt-to-equity ratio of 0.53. Agilent Technologies has a 52 week low of $96.43 and a 52 week high of $153.84. The stock has a market cap of $40.23 billion, a price-to-earnings ratio of 33.31, a P/E/G ratio of 4.53 and a beta of 1.26.

Agilent Technologies (NYSE:A - Get Free Report) last announced its quarterly earnings results on Wednesday, August 27th. The medical research company reported $1.37 EPS for the quarter, meeting analysts' consensus estimates of $1.37. The company had revenue of $1.74 billion during the quarter, compared to analysts' expectations of $1.67 billion. Agilent Technologies had a return on equity of 25.51% and a net margin of 17.97%.Agilent Technologies's revenue was up 10.1% compared to the same quarter last year. During the same period in the prior year, the company earned $1.32 EPS. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. Analysts expect that Agilent Technologies will post 5.58 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. grew its position in Agilent Technologies by 1.8% in the second quarter. Vanguard Group Inc. now owns 33,997,845 shares of the medical research company's stock worth $4,012,086,000 after acquiring an additional 589,219 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its stake in Agilent Technologies by 10.7% in the second quarter. Massachusetts Financial Services Co. MA now owns 13,227,387 shares of the medical research company's stock worth $1,560,964,000 after purchasing an additional 1,273,994 shares during the last quarter. Geode Capital Management LLC lifted its stake in Agilent Technologies by 1.6% in the second quarter. Geode Capital Management LLC now owns 7,319,530 shares of the medical research company's stock worth $860,137,000 after purchasing an additional 115,183 shares during the last quarter. Generation Investment Management LLP lifted its stake in Agilent Technologies by 15.9% in the second quarter. Generation Investment Management LLP now owns 5,775,860 shares of the medical research company's stock worth $681,609,000 after purchasing an additional 792,304 shares during the last quarter. Finally, Pictet Asset Management Holding SA lifted its stake in Agilent Technologies by 2.5% in the first quarter. Pictet Asset Management Holding SA now owns 5,341,870 shares of the medical research company's stock worth $624,888,000 after purchasing an additional 128,131 shares during the last quarter.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.